GLPwatch

Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice.

Physiol Rep · 2017

Last updated 2026-05-28

In a study using diabetic mice, researchers found that two treatments—insulin and the GLP-1 drug liraglutide—changed the levels of specific proteins in the kidneys in different ways. These changes were not primarily linked to the mice’s protein in urine or their blood sugar control.

AI summary of the abstract below.

JournalPhysiol Rep, 2017
Citations6
Relative citation ratio0.24
NIH percentile15
Molecules liraglutide
Conditions studied Type 2 Diabetes, Chronic Kidney Disease

Abstract

Diabetes mellitus (DM) is a worldwide disease that affects 9% of the adult world population and type 2 DM accounts for 90% of those. A common consequence of DM is kidney complications, which could lead to kidney failure. We studied the potential effects of treatment with insulin and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide on the diabetic kidney proteome through the use of the db/db mouse model system and mass spectrometry (MS). Multivariate analyses revealed distinct effects of insulin and liraglutide on the db/db kidney proteome, which was seen on the protein levels of, for example, pterin-4 -carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor-1 (PCBD1), neural precursor cell expressed developmentally down-regulated-8 (NEDD8), transcription elongation factor-B polypeptide-1 (ELOC) and hepcidin (HEPC). Furthermore, the separation of the insulin, liraglutide and vehicle db/db mouse groups in multivariate analyses was not mainly related to the albumin excretion rate (AER) or the level of glycated hemoglobin A (HbA%) in the mice. In summary, we show that insulin and liraglutide give rise to separate protein profiles in the db/db mouse kidney.

Verbatim abstract via PubMed 28330952 ↗

Related research